Vertex Pharmaceuticals Incorporated (VRTX) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP net income | 1.1B | FY2026-Q1 |
| ALYFTREK revenue | 424.4M | FY2026-Q1 |
| Outside the U.S. total revenue | 1.21B | FY2026-Q1 |
| U.S. total revenue | 1.78B | FY2026-Q1 |
| Non-GAAP effective tax rate | 19.60 percent | FY2026-Q1 |
| GAAP effective tax rate | 17.70 percent | FY2026-Q1 |
| Income from operations (GAAP) | 1.14B | FY2026-Q1 |
| Other product revenues | 237M | FY2025-Q4 |
Back to VRTX overview · VRTX earnings · VRTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.